Clinical Trial Update: Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2 [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating the safety and efficacy of 0.1% RGN-259 ophthalmic solution for neurotrophic keratopathy is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurotrophic Keratopathy

Drugs mentioned

• RGN-259 ophthalmic solution (RGN-259)

Snippet

Sponsor: ReGenTree, LLC | Conditions: Neurotrophic Keratopathy | Phase 3 | Status: RECRUITING